In this study, we employed a network meta-analysis to evaluate the efficacy (ORR, DCR, OS, and PFS) and safety (total AREs, neutropenia, diarrhea, and fatigue) of CDK4/6 inhibitors combined with ET in HR+/HER2-breast cancer. Here, CDK4 is linked to breast cancer.